论文部分内容阅读
肺动脉高压(PAH)是一类以小肺动脉血管重构为特征的恶性心肺血管疾病。5型磷酸二酯酶(PDE-5)抑制剂可减少环鸟苷酸的降解而舒张肺血管平滑肌,有效降低肺血管阻力。本文综述PDE-5抑制剂的作用机制、药动学及临床应用研究进展。
Pulmonary hypertension (PAH) is a type of malignant cardiovascular disease characterized by remodeling of small pulmonary arteries. Type 5 phosphodiesterase (PDE-5) inhibitors reduce the degradation of cyclic guanylate and relax the pulmonary vascular smooth muscle, effectively reducing pulmonary vascular resistance. This review summarizes the mechanism, pharmacokinetics and clinical application of PDE-5 inhibitors.